Palvella Therapeutics, Inc. Operating Lease Right-of-Use Assets
Palvella Therapeutics, Inc. (PVLA) had Operating Lease Right-of-Use Assets of $482.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-04
- 2026-06-30: Operating Lease, Right-of-Use Asset $482.00K.
- 2026-03-31: Operating Lease, Right-of-Use Asset $528.00K.
- 2025-12-31: Operating Lease, Right-of-Use Asset $572.00K.
- 2024-12-31: Operating Lease, Right-of-Use Asset $0.00.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $482.00K 10-Q · filed 2026-08-04 |
| 2026-03-31 | $528.00K 10-Q · filed 2026-05-07 |
| 2025-12-31 | $572.00K 10-Q · filed 2026-08-04 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-31 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-14 |
| 2023-06-30 | $3.82M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $3.80M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $3.71M 10-Q · filed 2023-11-14 |
| 2022-09-30 | $3.40M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $3.62M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $3.84M 10-Q · filed 2022-05-11 |
| 2021-12-31 | $3.91M 10-K · filed 2023-03-31 |
| 2021-09-30 | $3.97M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $3.86M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $3.79M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $3.93M 10-K · filed 2022-03-02 |
| 2020-09-30 | $3.68M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $3.27M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $3.17M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $3.44M 10-K · filed 2021-03-31 |
| 2019-01-01 | $868.00K 10-K · filed 2020-03-13 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |